Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 17/20 | 0.59 |
| ▸ | MMP13 | P45452 | 17/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 17/20 | 0.59 |
| ▸ | MMP9 | P14780 | 16/20 | 0.59 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609480 | 0.93 | MMP1 (0.69) | MMP1MMP13ADAM17MMP9MAPT | |
| SCHEMBL6612830 | 0.92 | MMP1 (0.53) | MMP1MMP13ADAM17MMP9MAPT | |
| SCHEMBL6607945 | 0.90 | MMP1 (0.54) | MMP1MMP13ADAM17MMP9AVPR2 | |
| SCHEMBL6614506 | 0.90 | MMP1 (0.54) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL6610535 | 0.89 | MMP1 (0.73) | MMP1MMP13ADAM17MMP9AVPR2 | |
| SCHEMBL6611911 | 0.89 | MMP1 (0.57) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL6611079 | 0.87 | MMP1 (0.53) | MMP1MMP13ADAM17MMP9MAPT | |
| SCHEMBL6610383 | 0.87 | MMP13 (0.56) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL6610057 | 0.86 | MMP1 (0.55) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL6608690 | 0.86 | MMP1 (0.51) | MMP1MMP13ADAM17MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544984-B1 | Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. | AMERICAN CYANAMID COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1147095-A1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1051407-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000044730-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6071903-A | ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-06-06 | — | — | US | disclosed |
| WO-1999037625-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |